Kidney and Super Speciality Ltd, a regional services provider, has announced the launch of its set to open on December 22, 2025.
The company has fixed the price band at ₹108 – ₹114 per equity share, with a face value of ₹2 each. The IPO is a fresh issue of up to 2.20 crore equity shares, aimed at supporting the company’s growth and expansion plans.
Investors can bid for a minimum of 128 equity shares, and in multiples thereof. As of date, the company has 5.68 crore equity shares outstanding.
The IPO will conclude on December 24, 2025.
The IPO is being made through the book-building process, with up to 75 per cent of the net offer reserved for qualified institutional buyers (QIBs), 15 per cent for non-institutional investors (NIIs) and 10 per cent for retail individual investors (RIIs).
Nirbhay Capital Services Private Limited is acting as the book-running lead manager to the issue, while MUFG Intime India Limited has been appointed as the registrar.
The equity shares are proposed to be listed on the BSE and NSE, subject to regulatory approvals.
Gujarat Kidney and Super Speciality operates a chain of mid-sized multi-speciality hospitals focused on secondary and tertiary healthcare services. On a consolidated basis, the company runs seven multispeciality hospitals and four in-house pharmacies across Gujarat, including facilities in Vadodara, Godhra, Bharuch, Borsad and Anand. The hospital network has a total bed capacity of 490 beds, with an operational capacity of 340 beds.
The company provides a wide range of integrated healthcare services, including diagnostics and pharmacy support, and has strategically focused on under-penetrated healthcare markets in Gujarat, offering affordable and quality medical care.
For the financial year ended March 31, 2025, Gujarat Kidney and Super Speciality Limited reported revenue from operations of ₹40.24 crore and a net profit of ₹9.49 crore. For the three months ended June 30, 2025, revenue stood at ₹15.26 crore, while net profit was ₹5.40 crore, reflecting improved profitability.